Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN SODIUM 12 500 UNITS IN DEXTROSE 5 versus PRADAXA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN SODIUM 12 500 UNITS IN DEXTROSE 5 versus PRADAXA.
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% vs PRADAXA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin binds to antithrombin III, inducing a conformational change that accelerates the inhibition of thrombin (factor IIa) and activated factor X (Xa), thereby preventing fibrin clot formation and extension.
Direct thrombin inhibitor; binds reversibly to the active site of thrombin, preventing fibrinogen cleavage and subsequent thrombus formation.
Loading dose: 5000 units IV bolus, then continuous IV infusion at 12,000-18,000 units/24h (10-15 units/kg/h). Adjust to target aPTT 60-80 seconds.
150 mg orally twice daily; for patients with CrCl 15-30 mL/min, 75 mg orally twice daily.
None Documented
None Documented
The terminal elimination half-life of heparin is dose- and concentration-dependent, averaging 1-2 hours after intravenous administration. At therapeutic doses, the half-life is approximately 1.5 hours; with higher doses, it can extend to 2.5-3 hours. The half-life is prolonged in patients with hepatic or renal impairment.
12–17 hours (terminal); prolonged to 18–35 hours in severe renal impairment (CrCl <30 mL/min); supports twice-daily dosing
Heparin is eliminated primarily via the reticuloendothelial system and liver, with renal excretion of metabolites accounting for approximately 50-60% of the dose. A small fraction (up to 5%) is excreted unchanged in urine. No significant biliary or fecal elimination.
Renal (80% unchanged); fecal/biliary (20% as inactive metabolites via P-glycoprotein-mediated secretion)
Category A/B
Category C
Anticoagulant
Anticoagulant